Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.68 |
| ▸ | CA2 | P00918 | 4/20 | 0.68 |
| ▸ | CA12 | O43570 | 3/20 | 0.68 |
| ▸ | CA7 | P43166 | 3/20 | 0.68 |
| ▸ | CA9 | Q16790 | 3/20 | 0.68 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.68 |
| ▸ | ESR1 | P03372 | 1/20 | 0.68 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | MAOA | P21397 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.54 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27647572 | 0.91 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL87450 | 0.89 | CA1 (0.83) | CA1CA2CA12CA7CA9 | |
| SCHEMBL11769771 | 0.87 | CA1 (0.73) | CA1CA2CA12CA7CA9 | |
| SCHEMBL27667926 | 0.87 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL21440358 | 0.87 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL27419624 | 0.87 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL29504635 | 0.87 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL7746905 | 0.87 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL30271267 | 0.87 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL27667923 | 0.87 | CA1 (0.79) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9885008-B2 | Photolabile pro-fragrances | HENKEL AG & CO. KGAA (DE) | 2018-02-06 | — | — | US | disclosed |
| US-9885008-B2 | Photolabile pro-fragrances | HENKEL AG & CO. KGAA (DE) | 2018-02-06 | — | — | US | disclosed |
| US-9885008-B2 | Photolabile pro-fragrances | HENKEL AG & CO. KGAA (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20160186103-A1 | PHOTOLABILE PRO-FRAGRANCES | HENKEL AG & CO. KGAA | 2016-06-30 | — | — | US | disclosed |
| US-20160186103-A1 | PHOTOLABILE PRO-FRAGRANCES | HENKEL AG & CO. KGAA | 2016-06-30 | — | — | US | disclosed |
| US-20160186103-A1 | PHOTOLABILE PRO-FRAGRANCES | HENKEL AG & CO. KGAA | 2016-06-30 | — | — | US | disclosed |
| US-9312041-B2 | Photolabile pro-fragrances | HENKEL AG & CO. KGAA (DE) | 2016-04-12 | — | — | US | disclosed |
| US-9312041-B2 | Photolabile pro-fragrances | HENKEL AG & CO. KGAA (DE) | 2016-04-12 | — | — | US | disclosed |
| US-9312041-B2 | Photolabile pro-fragrances | HENKEL AG & CO. KGAA (DE) | 2016-04-12 | — | — | US | disclosed |
| EP-2726051-A1 | PHOTOLABILE PRO-FRAGRANCES | Henkel AG & Co. KGaA (DE) | 2014-05-07 | — | — | EP | disclosed |
| US-20110112089-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-7915300-B2 | Especially those of papain superfamily; prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin K; (3aS,6S,6aS)-6-Fluoro-4-{(S)-4-methyl-2-[(R)-2,2,2-trifluoro-1-(4'-methanesulfonylbiphenyl-4-yl)-ethylamino]-pentanoyl}-tetrahydro-furo[3,2-b]pyrrol-3-one | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| CN-100469780-C | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2009-03-18 | — | — | CN | disclosed |
| US-20080234260-A1 | Cysteine Protease inhibitors | MEDIVIR AB (SE) | 2008-09-25 | — | — | US | disclosed |
| WO-2005066180-A9 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-09-25 | — | — | WO | disclosed |
| CN-1918169-A | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| WO-2007006714-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| EP-1701960-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005066180-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| CN-1265651-A | Novel tricyclic compound having saturated ring and pharmaceutical composition thereof | ASAHI CHEMICAL IND (JP) | 2000-09-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160186103-A1 | PHOTOLABILE PRO-FRAGRANCES | CUTA, TRPA1, PIR | CA1 4134/4885CA2 4607/4885CA12 4348/4885 |
| US-20080234260-A1 | Cysteine Protease inhibitors | CTSS, CTSZ, CTSK | CA1 216/4885CA2 720/4885CA12 1351/4885 |
| US-20110112089-A1 | Cysteine Protease Inhibitors | CTSS, CTSZ, CTSK | CA1 347/4885CA2 1013/4885CA12 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.